Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Dec 22, 2011

PTC THERAPEUTICS' ANTIBACTERIAL PROGRAM RECEIVES $5 MILLION AWARD FROM THE WELLCOME TRUST

- Second PTC Discovery Program Funded by Seeding Drug Discovery Award -

Nov 29, 2011

Roche signs agreement with PTC Therapeutics to advance treatment for Spinal Muscular Atrophy (SMA)

Collaboration offers new hope for a potential treatment for the leading genetic cause of death in infants and toddlers

Nov 07, 2011

PTC Therapeutics Receives Grand Challenges Explorations Funding

South Plainfield, NJ– November 7, 2011 - PTC Therapeutics, Inc. announced today that it will receive funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to test unorthodox ideas that address persistent health

Sep 02, 2011

PTC THERAPEUTICS AND GENZYME ANNOUNCE RESTRUCTURING OF COLLABORATION

- PTC Regains Worldwide Rights to Ataluren in Duchenne and Becker Muscular Dystrophies -

Jul 01, 2011

ATALUREN PHASE 2 DATA IN NONSENSE MUTATION CYSTIC FIBROSIS PUBLISHED IN THE EUROPEAN RESPIRATORY JOURNAL

SOUTH PLAINFIELD, NJ – July 1, 2011 – PTC Therapeutics, Inc. (PTC) today announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal.

Jun 29, 2011

ASTRAZENECA AND PTC THERAPEUTICS ANNOUNCE STRATEGIC ONCOLOGY DRUG DISCOVERY COLLABORATION WITH POTENTIAL EXTENSION TO OTHER THERAPEUTIC AREAS

ALDERLEY PARK, UK and SOUTH PLAINFIELD, N.J., June 29, 2011 – AstraZeneca and PTC Therapeutics, Inc. (PTC) today announced that they have entered into an exclusive research collaboration and license agreement for the application of PTC's proprietary GEMS™ technology (Gene Expression Modulation by

Mar 30, 2011

PTC THERAPEUTICS APPOINTS ROBERT SPIEGEL, M.D. AS CHIEF MEDICAL OFFICER

- Jay Barth, M.D. Promoted to Vice President of Clinical Development -

Mar 02, 2011

PTC Therapeutics Announces Achievement of Milestone in BMI1 Collaboration with the Wellcome Trust

- PTC Receives $2.2 Million Payment -

Feb 01, 2011

PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients

- PPMD awards $250,000 grant towards research program-

Jan 19, 2011

PTC THERAPEUTICS' PRESIDENT AND CEO ELECTED AAAS FELLOW

SOUTH PLAINFIELD, NJ – January 19, 2011 – Stuart W. Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. (PTC), has been elected a Fellow of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society and publisher of the journal Science.

Pagination

First page
Previous page
…
Page 54
Page 55
Current page 56
Page 57
Next page
Last page